StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — BOB Capital Markets

BUYEmcure Pharmaceuticals Limited

byBOB Capital MarketsHorizon: NA (inferred 1 year)6 May 2026via Institutional / Brokerage Research

Entry₹1,659.5Inferred
Target₹1,965
Total upside +18.41% (call closed)
Stop lossNot given
Exit₹1,96531 Jul 2026, 12:07 pm
Target hit+18.41%0.00%upside left
Follow BOB Capital Markets for new calls(63% target hit, 356 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 7 active Long-term calls on EMCURESee 36 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 31 Jul 2026
10 supporting1 neutral2 opposing
Supports the BUY call (10)

Emcure Pharmaceuticals Ltd has completed the acquisition of shares in Gennova Biopharmaceuticals Limited, indicating a strategic expansion.

BSE · Company Update·22 Jul · 1w ago

(opens in new tab)

Emcure Pharmaceuticals has received CDSCO approval to expand the use of its drug Poviztra for MASH indication, potentially increasing market reach and revenue.

BSE · Company Update·20 Jul · 1w ago

(opens in new tab)

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·20 Jul · 2w ago

Novo Nordisk's Wegovy wins India nod for fatty liver disease; Emcure to distribute

NewsCnbc-Tv18·17 Jul · 2w ago

(opens in new tab)

Emcure Pharmaceuticals Ltd's press release indicates consolidation of Gennova ownership and a sharpened focus on biologics, with Samit Mehta leading growth.

BSE · Company Update·13 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (1)

Nothing found in this tip’s window yet.

Weighs against the BUY call (2)

Stocks in news: CDSL, Adani Energy, L&T, Adani Total Gas, Emcure Pharma

NewsEt-Markets·21 Jul · 1w ago

(opens in new tab)

Emcure Pharmaceuticals gets CDSCO nod for MASH treatment in adults with liver fibrosis

NewsCnbc-Tv18·20 Jul · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.